Biomedical 

The company is a platform-based innovative drug company specializing in precision oncology, multidrug-resistant bacterial infections, and metabolic diseases. The company has built three world-class technology platforms for targeted tumor therapy, anti-infection, and targeted protein degradation(TPD). Its innovative drug pipeline includes β-lactamase(BLI) inhibitors, histone methyltransferase(EZH2) inhibitors, human urate transporter 1(hURAT1) inhibitors, and next-generation ADC therapies. 

Seeking Pre-IPO round financing. 

Mr. Zhang 

18019023928 

Biomedical 

Founded in 2009, The company is a multinational biopharmaceutical company dedicated to developing cell immunotherapies for the treatment of solid tumors. The company aims to cure patients with advanced tumors using innovative cell therapy technologies and become a global leader in cell therapy. Innovative Cellular Therapeutics' leading product, GCC19CART, has demonstrated significant efficacy in treating patients with advanced colorectal cancer and is expected to become the world's first approved (First-in-Class) CAR-T therapy for colorectal cancer. 

Specific financing amount not explicitly mentioned; implies needs for advancing listing and commercialization cooperation. 

Mr. Zhang 

18019023928 

Biomedical 

The company is an innovative biopharmaceutical company specializing in therapies for endocrine-related disorders. In 2021, the company completed a USD 150 million Series B financing round. In 2022, its Phase III clinical trial of Lonapegsomatropin(TransCon hGH) in China successfully achieved its primary endpoint. In 2023, VISEN was listed on the Hurun Global Unicorn Index and recognized as one of KPMG China's Top 50 Biotech Innovation Companies. 

Specific financing needs for this round not explicitly mentioned; implies needs for subsequent commercialization and international cooperation. 

Mr. Zhang 

18019023928 

Biomedical 

Founded in 2007, the company was the first company to apply Cadmium Zinc Telluride(CZT) semiconductor detectors to medical imaging. It developed the world’s first digital dedicated cardiac Single-Photon Emission Computed Tomography(SPECT) system, the D-Spect. Today, D-Spect ranks first in the global dedicated cardiac SPECT equipment market, commanding over half of the worldwide market share. 

Specific financing needs not explicitly mentioned; implies market expansion needs. 

Mr. Zhang 

18019023928 

Biomedical 

The company is committed to automating biopharmaceutical production, reducing labor dependency. Its fully enclosed technology removes the need for high-level cleanroom environments, transforming the industry 's cost structure. Digital intelligence technology enables full-process traceability, converting production data into actionable elements. 

Specific financing needs not explicitly mentioned; implies industrialization promotion needs. 

Mr. Zhang 

18019023928 

Biomedical 

Founded in 2020, the company is focused on developing fully domestically produced upstream equipment for high-throughput sequencing and establishing a globally leading sequencing and spatial-omics platform. Its products have obtained EU CE certification and are marketed overseas, and the domestic Class III medical device registration certificate is expected to be granted within 2024. The project proponents plan to invest to establish production pipelines and R&D centers. 

Plans to invest in establishing production pipelines and R&D centers (implies financing or cooperation needs). 

Mr. Zhang 

18019023928 

Biomedical 

The project offers a comprehensive solution for interventional treatment of venous thrombosis, encompassing a range of proprietary products, including catheters of various calibers for thrombectomy, laser-cut stent retrievers, intelligent thrombus aspiration pumps, smart waterjet therapy devices, and large-bore guiding sheaths. These products are designed to address acute, subacute, and chronic thrombosis interventions. The company has secured multiple invention patents and has several PCT international patent applications pending. 

Specific financing needs not explicitly mentioned; implies market promotion and international cooperation needs. 

Mr. Chen 

18918882980 

Biomedical 

The company, established in May 2013 is pioneering the 4.0 non-invasive era for the treatment of tumors and nervous system diseases, following the chemical, majorly invasive, and minimally invasive treatment eras. Proceeds from the listing will be primarily allocated to R&D, clinical registration and certification (including U.S. FDA), equipment manufacturing, market promotion, A-share institutional service fees, and expansion into overseas markets. 

Financing for R&D investment, clinical registration and certification (including U.S. FDA), equipment manufacturing, market promotion, A-share institutional service fees, and expansion into overseas markets. 

Mr. Chen 

18918882980 

Biomedical 

The company focuses on non-invasive brain-computer interface technology, concentrating on the field of neuro and mental rehabilitation medical equipment. It engages in product research and development, production and sales, and is committed to providing comprehensive brain science and psychology research, diagnosis and treatment, and rehabilitation solutions for the health industry. It aims to promote technological progress and application innovation in the field of brain-computer interfaces. 

Specific financing needs not explicitly mentioned; implies market promotion needs. 

Mr. Chen 

18918882980 

Biomedical 

The company was established in July 2021 with focus on development of innovative gene therapy products for ophthalmic diseases. The company has built up innovative platforms and pipelines of global potential, and has achieved clinical proof of concept. 

Specific financing needs not explicitly mentioned; implies clinical advancement and cooperation needs. 

Mr. Chen 

18918882980